Scarica l'app Stockscreener
23.75
4.66%
-1.16
Dopo l'orario di chiusura:
23.67
-0.08
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$24.91
Aprire:
$24.725
Volume 24 ore:
12.41M
Relative Volume:
1.14
Capitalizzazione di mercato:
$9.24B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.7205
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-6.31%
1M Prestazione:
-16.64%
6M Prestazione:
-13.98%
1 anno Prestazione:
-55.64%
Intervallo 1D:
$23.71
$25.15
Intervallo di 1 settimana:
$23.71
$29.20
Portata 52W:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
23.75 | 9.73B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA): Assessing Valuation as Cancer Therapy Pipeline Expands with New Multiple Myeloma Trial - Yahoo Finance
Should You Buy Moderna Stock Ahead of Q3 Earnings Report? - sharewise.com
Here’s why Moderna is sliding - Traders Union
17,216 Shares in Moderna, Inc. $MRNA Purchased by Corton Capital Inc. - MarketBeat
Can Moderna Inc. stock hit record highs againWeekly Stock Summary & Long-Term Growth Stock Strategies - newser.com
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - USA Today
Nisa Investment Advisors LLC Sells 23,279 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc. Stock Slides 8.3%, Underperforms Peers - 富途牛牛
Revaccination With mRNA-1345 for RSV Maintains Robust Immunogenicity, Safety - Vaccine Advisor
Moderna begins first patient dosing in multiple myeloma trial - Investing.com India
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
Inside Biotech: Moderna opens new front in oncology with T-cell engager therapy - Proactive financial news
Moderna Stock Is Sliding Monday: What's Going On? - Benzinga
Moderna Stock Falls on Revenue Decline and Clinical Trial SetbackNews and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Falling Today - Yahoo Finance
Moderna (MRNA) Begins Phase 1/2 Trial for mRNA-2808 in Multiple Myeloma - GuruFocus
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Tacoma News Tribune
Moderna (NASDAQ: MRNA) starts Phase 1/2 trial dosing mRNA-2808 for multiple myeloma - Stock Titan
Moderna, Inc. $MRNA Shares Sold by South Dakota Investment Council - MarketBeat
Will Moderna Inc. stock benefit from sector rotationDollar Strength & Growth Oriented Trade Recommendations - newser.com
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Is it too late to sell Moderna Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Is Moderna Inc. stock in correction or buying zoneAnalyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
How moving averages guide Moderna Inc. tradingJuly 2025 Rallies & AI Powered Buy and Sell Recommendations - newser.com
Moderna Stock Soars 13.93%, Hits Intraday High of $29.20 - Markets Mojo
GAM Holding AG Invests $276,000 in Moderna, Inc. $MRNA - MarketBeat
Wealthfront Advisers LLC Has $521,000 Stake in Moderna, Inc. $MRNA - MarketBeat
New York Life Investment Management LLC Acquires 31,327 Shares of Moderna, Inc. $MRNA - MarketBeat
Applying Wyckoff theory to Moderna Inc. stock2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening? - Smartkarma
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - York Dispatch
Y Intercept Hong Kong Ltd Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Moderna, Inc. $MRNA - MarketBeat
Asset Management One Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock benefits from tech adoptionJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Moderna (NASDAQ:MRNA) Stock Price Up 9.5%Time to Buy? - MarketBeat
Moderna Stock Falls, Reversing Some Buyout Rally Gains | 2025News and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna: Focus On Cancer Vaccines, Not Buyout (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?Moderna (NASDAQ:MRNA) - Benzinga
Moderna (MRNA) Stock Retreats After Acquisition Speculation Surge - GuruFocus
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Best data tools to analyze Moderna Inc. stockWeekly Stock Report & Precise Buy Zone Identification - newser.com
Why Moderna Inc. stock is favored by top institutions2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline - sharewise.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Will Moderna Inc. stock gain from strong economyWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - Worcester Telegram
Using Ichimoku Cloud for Moderna Inc. technicalsForecast Cut & Daily Profit Focused Screening - newser.com
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - columbiadailyherald.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):